Lamisil and Fatty liver - a phase IV clinical study of FDA data

Summary:

Fatty liver is reported as a side effect among people who take Lamisil (terbinafine hydrochloride), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Foradil, and have Nail tinea.

The phase IV clinical study analyzes which people have Fatty liver when taking Lamisil. It is created by eHealthMe based on reports of 13,455 people who have side effects when taking Lamisil from the FDA, and is updated regularly.

What is Lamisil?

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 14,080 Lamisil users. Check the latest studies of Lamisil.

What is Fatty liver?

Fatty liver is found to be associated with 260 drugs and 105 conditions by eHealthMe. Check the latest studies of Fatty liver.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

13,455 people reported to have side effects when taking Lamisil.
Among them, 11 people (0.08%) have Fatty liver.

Among these 11 people:

How long have people been on Lamisil when they have Fatty liver? *

What is the gender of people who have Fatty liver when taking Lamisil? *

female: 36.36 %
male: 63.64 %

What is the age of people who have Fatty liver when taking Lamisil? *

What are other drugs people take besides Lamisil? *

What are other side effects people have besides Fatty liver? *

Haemoglobin Decreased: 6 people, 54.55%
Weakness: 6 people, 54.55%
Fever: 6 people, 54.55%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 45.45%
Multi-Organ Failure (multisystem organ failure): 5 people, 45.45%
Nosebleed (bleeding from nose): 5 people, 45.45%
Hemiparesis (weakness on one side of the body): 5 people, 45.45%
Bleeding Into The Skin: 5 people, 45.45%
Blood Bilirubin Increased: 5 people, 45.45%
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin): 4 people, 36.36%

What are the existing conditions these people have? *

Nail Tinea (fungal infection of nail): 2 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Lamisil and have Fatty liver?

- Check whether Fatty liver is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lamisil:

Lamisil (14,080 reports)

Fatty liver treatments and more:

Fatty liver (3,197 reports)

Browse all side effects of Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fatty liver:

Fatty liver (260 drugs)

Browse all the conditions that are associated with Fatty liver:

Fatty liver (105 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on terbinafine hydrochloride (the active ingredients of Lamisil) and Lamisil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.